GYN: Endometrial/Uterine Cancer Clinical Trials

A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

Primary Objective: To assess the activity of Afatinib in patients with persistent or recurrent uterine serous carcinoma overexpressing HER2/neu with the frequency of patients who survive progressio...

Diagnosis: GYN: Endometrial/Uterine Cancer

Phase: 2

Protocol Number:

Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer

This research study is evaluating a drug called Avelumab as a possible treatment for recurrent or Metastatic Endometrial Cancer.

Diagnosis: GYN: Endometrial/Uterine Cancer

Phase: 2

Protocol Number: 16-322

Study of IMGN853 in Comb. With Bevacizumab, Carboplatin, PLD or Pembrolizumab in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer

This is a phase 1b study to assess the safety, tolerability, and preliminary anti-tumor activity of IMGN853 when administered with chemotherapy. Patients will be assigned to one of four regimens: I...

Diagnosis: GYN: Endometrial/Uterine Cancer, GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase: 1

Protocol Number: 15-505

Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix

Proton beam radiation therapy is known to spare surrounding normal tissues from radiation. Proton beam radiation delivers less radiation beyond the area of the target tissues. This may reduce side ...

Diagnosis: GYN: Endometrial/Uterine Cancer, GYN: Cervical Cancer

Phase: N/A

Protocol Number: 10-269

Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer

The primary purpose of this study is to determine if MLN0128 in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.

Diagnosis: GYN: Endometrial/Uterine Cancer

Phase:

Protocol Number: 16-296

The HOPE Trial:Helping Our Patients Excel

This research study is evaluating a new smartphone application named the "Helping Our Patients Excel (HOPE)" app with Fitbit devices. The HOPE app was designed to learn about improving qu...

Diagnosis: GYN: Endometrial/Uterine Cancer, GYN: Ovarian, Fallopian, Peritoneal Cancer, GYN: Cervical Cancer

Phase:

Protocol Number: 16-477

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

The purpose of this study of MCS110 with PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with P...

Diagnosis: GYN: Endometrial/Uterine Cancer, Melanoma, Pancreatic Cancer, Breast: Early Stage Disease

Phase:

Protocol Number: 16-491

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

This research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in combination with radiation therapy as a possible treatment for recurrent or metastatic gynecologic cancer....

Diagnosis: GYN: Endometrial/Uterine Cancer, GYN: Vulvar Cancer, Radiation Oncology, GYN: Ovarian, Fallopian, Peritoneal Cancer, GYN: Cervical Cancer

Phase:

Protocol Number: 17-382

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

First-in-human, Phase 1b safety study of the antibody-drug conjugate (ADC) XMT-1536 administered as an intravenous infusion once every three weeks. Patients with tumor types likely to express NaPi2...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Thyroid Cancer, GYN: Endometrial/Uterine Cancer, Solid Tumor/Phase I, Lung Cancer

Phase:

Protocol Number: 17-621

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer (P204)

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovaria...

Diagnosis: GYN: Endometrial/Uterine Cancer, GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 17-499

Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer

This randomized phase II trial studies how well cabozantinib and nivolumab work in treating patients with endometrial that has come back or spread to other places in the body. Cabozantinib may stop...

Diagnosis: GYN: Endometrial/Uterine Cancer

Phase:

Protocol Number: 18-715

A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma

This research study is studying an investigational drug as a possible treatment for uterine cancer. The drug involved in this study is: -AZD1775

Diagnosis: GYN: Endometrial/Uterine Cancer

Phase:

Protocol Number: 18-316

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

This research study is studying a drug combination as a possible treatment for endometrial cancer. The drugs involved in this study are: - mirvetuximab soravtansine (IMGN853) - pembrolizumab

Diagnosis: GYN: Endometrial/Uterine Cancer

Phase:

Protocol Number: 18-602

The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine Fibroids

This research is being done to test new MRI methods called Magnetic Resonance Fingerprinting and Q-space Trajectory Imaging in gynecological abnormalities. The purpose of this research study is to ...

Diagnosis: GYN: Endometrial/Uterine Cancer

Phase:

Protocol Number: 19-056